Inhibrx Biosciences(INBX)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

INBX Inhibrx Biosciences

交易中 06-17 13:01:45 EDT

95.92

+2.81

+3.01%

最高95.96	最低91.94	成交量13.07万
今开93.69	昨收93.11	日振幅4.32%
总市值14.07亿	流通市值7.49亿	总股本1,467万
成交额1,234万	换手率1.67%	流通股本780.85万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"INBX","market":"US","secType":"STK","nameCN":"Inhibrx Biosciences","latestPrice":95.915,"timestamp":1781715665288,"preClose":93.11,"halted":0,"volume":130700,"delay":0,"changeRate":0.03012565782407912,"floatShares":7808544,"shares":14671186,"eps":-8.390236,"marketStatus":"交易中","change":2.805,"latestTime":"06-17 13:01:45 EDT","open":93.69,"high":95.96,"low":91.94,"amount":12343362.894000001,"amplitude":0.043175,"askPrice":96.37,"askSize":15,"bidPrice":96.01,"bidSize":1,"shortable":3,"etf":0,"ttmEps":-8.390236,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1781726400000},"marketStatusCode":2,"adr":0,"exchange":"NASDAQ","adjPreClose":93.11,"preHourTrading":{"tag":"盘前","latestPrice":96.37,"preClose":93.11,"latestTime":"08:50 EDT","volume":95,"amount":9359.99945,"timestamp":1781700610838,"change":3.26,"changeRate":0.035012,"amplitude":0.025883},"postHourTrading":{"tag":"盘后","latestPrice":93.11,"preClose":93.11,"latestTime":"17:26 EDT","volume":15,"amount":1396.65,"timestamp":1781645219396,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.690022,"impliedVol":0.7817,"impliedVolPercentile":0.1434},"requestUrl":"/m/hq/s/INBX","defaultTab":"news","newsList":[{"id":"1174269329","title":"Inhibrx宣布美国FDA受理Ozekibart用于治疗常规软骨肉瘤患者的生物制品许可申请","url":"https://stock-news.laohu8.com/highlight/detail?id=1174269329","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1174269329?lang=zh_cn&edition=full","pubTime":"2026-06-15 21:16","pubTimestamp":1781529384,"startTime":"0","endTime":"0","summary":"Inhibrx Biosciences（INBX）宣布，其用于治疗常规软骨肉瘤患者的在研药物Ozekibart的生物制品许可申请（BLA）已获得美国食品药品监督管理局（FDA）的受理。FDA的受理标志着该药物审评流程的正式启动，是向潜在获批迈出的关键一步。常规软骨肉瘤是一种罕见的骨癌，目前治疗选择有限，此次BLA的受理为患者带来了新的希望。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INBX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1169839556","title":"Inhibrx Biosciences公司：Inbrx-106联合帕博利珠单抗观察到三例完全影像学缓解","url":"https://stock-news.laohu8.com/highlight/detail?id=1169839556","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1169839556?lang=zh_cn&edition=full","pubTime":"2026-05-11 20:06","pubTimestamp":1778501162,"startTime":"0","endTime":"0","summary":"Inhibrx Biosciences公司宣布，其候选药物Inbrx-106与帕博利珠单抗（Pembrolizumab）联合治疗的临床研究中，已观察到三例患者达到完全影像学缓解。\n这一积极数据展现了该联合疗法在特定患者群体中的显著抗肿瘤活性。完全影像学缓解通常意味着通过影像学检查（如CT或MRI）已无法检测到肿瘤病灶，是评估癌症治疗效果的一个重要指标。\n该结果进一步支持了Inbrx-106的开发潜力，为后续临床研究提供了有力依据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INBX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1181018288","title":"Inhibrx Biosciences公司：Inbrx-106联合帕博利珠单抗确认客观缓解率达44.0%，显著优于单药21.4%","url":"https://stock-news.laohu8.com/highlight/detail?id=1181018288","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1181018288?lang=zh_cn&edition=full","pubTime":"2026-05-11 20:05","pubTimestamp":1778501143,"startTime":"0","endTime":"0","summary":"Inhibrx Biosciences公司公布了其候选药物Inbrx-106与帕博利珠单抗联合疗法的积极数据。结果显示，该联合方案取得了44.0%的确认客观缓解率，而单独使用帕博利珠单抗的对照组，其确认客观缓解率仅为21.4%。这一数据对比凸显了联合疗法在疗效上的显著优势。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INBX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1160098811","title":"Inhibrx Biosciences公司：Inbrx-106联合帕博利珠单抗或使系统性T细胞扩增提升高达15倍","url":"https://stock-news.laohu8.com/highlight/detail?id=1160098811","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1160098811?lang=zh_cn&edition=full","pubTime":"2026-05-11 20:02","pubTimestamp":1778500935,"startTime":"0","endTime":"0","summary":"Inhibrx Biosciences公司公布的最新研究数据显示，其候选药物Inbrx-106与帕博利珠单抗联合使用时，可能引发系统性T细胞扩增高达15倍的显著提升。这一发现预示着该联合疗法在激活人体免疫系统对抗肿瘤方面具有巨大潜力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INBX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1144007889","title":"Inhibrx公布INBRX-106一线治疗HNSCC的2期中期数据；初步结果显示其较PD-1单药疗法具有潜在共刺激优势","url":"https://stock-news.laohu8.com/highlight/detail?id=1144007889","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1144007889?lang=zh_cn&edition=full","pubTime":"2026-05-11 20:01","pubTimestamp":1778500907,"startTime":"0","endTime":"0","summary":"Inhibrx Biosciences  公布了其候选药物INBRX-106在一线治疗头颈部鳞状细胞癌患者中的2期临床试验中期数据。初步分析表明，INBRX-106可能展现出超越现有PD-1单药疗法的共刺激活性优势，为这一治疗领域带来了新的希望。头颈部鳞状细胞癌的治疗长期面临挑战，尽管免疫检查点抑制剂如PD-1单抗已取得进展，但疗效提升空间依然显著。公司表示，这些数据支持继续推进INBRX-106的临床开发计划。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INBX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1123068912","title":"Inhibrx 将举办网络直播 提供一线HNSCC中Inbrx-106六边形研究临床进展更新","url":"https://stock-news.laohu8.com/highlight/detail?id=1123068912","media":"美股速递","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1123068912?lang=zh_cn&edition=full","pubTime":"2026-05-09 04:01","pubTimestamp":1778270476,"startTime":"0","endTime":"0","summary":"Inhibrx Biosciences (INBX) 计划通过一场网络直播会议，对外公布其候选药物 Inbrx-106 在一线治疗头颈部鳞状细胞癌 (HNSCC) 的“六边形”研究中的最新临床数据。此次更新旨在向投资者和医学界提供该试验项目进展的关键信息。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INBX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1111467807","title":"Inhibrx Biosciences盘前大涨6.2% 路透报道其实验性抗癌药物引默克及同业竞逐","url":"https://stock-news.laohu8.com/highlight/detail?id=1111467807","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1111467807?lang=zh_cn&edition=full","pubTime":"2026-04-22 19:08","pubTimestamp":1776856092,"startTime":"0","endTime":"0","summary":"生物科技公司Inhibrx Biosciences股价在盘前交易中强势攀升6.2%，此前路透社报道称，该公司旗下的一款实验性抗癌药物已吸引制药巨头默克及其竞争对手的收购兴趣。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","INBX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1156179722","title":"Inhibrx将举办网络直播会议 公布Ozekibart (INBRX-109)治疗晚期结直肠癌临床进展","url":"https://stock-news.laohu8.com/highlight/detail?id=1156179722","media":"美股速递","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1156179722?lang=zh_cn&edition=full","pubTime":"2026-04-21 05:05","pubTimestamp":1776719114,"startTime":"0","endTime":"0","summary":"Inhibrx Biosciences（纳斯达克代码：INBX）宣布将举办专题网络直播会议，重点介绍其核心候选药物Ozekibart（研发代号：INBRX-109）在晚期结直肠癌治疗领域的最新临床数据。此次会议将面向投资者和医学界专业人士，深入解析该药物在末线治疗中的疗效与安全性表现。\n公司管理层及临床研究负责人将出席本次会议，通过详实的数据展示与案例分析，全面呈现Ozekibart在难治性结直肠癌患者群体中的治疗潜力。与会者可通过在线平台实时参与互动研讨，获取第一手临床研究进展信息。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INBX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2600018204","title":"Inhibrx Biosciences, Inc.盘中异动 下午盘股价大跌5.04%","url":"https://stock-news.laohu8.com/highlight/detail?id=2600018204","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2600018204?lang=zh_cn&edition=full","pubTime":"2026-01-03 04:01","pubTimestamp":1767384069,"startTime":"0","endTime":"0","summary":"北京时间2026年01月03日04时01分，Inhibrx Biosciences, Inc.股票出现波动，股价急速下挫5.04%。Inhibrx Biosciences, Inc.股票所在的生物技术行业中，整体跌幅为0.08%。Inhibrx Biosciences, Inc.公司简介：Inhibrx Biosciences Inc是一家临床阶段的生物制药公司，利用其专有的模块化蛋白质工程平台开发了一系列新型生物治疗候选药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260103040109a4957eea&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260103040109a4957eea&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["INBX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517645901","title":"Inhibrx Biosciences, Inc.盘中异动 大幅下跌5.99%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517645901","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517645901?lang=zh_cn&edition=full","pubTime":"2025-03-06 23:25","pubTimestamp":1741274709,"startTime":"0","endTime":"0","summary":"北京时间2025年03月06日23时25分，Inhibrx Biosciences, Inc.股票出现异动，股价大幅跳水5.99%。Inhibrx Biosciences, Inc.股票所在的生物技术行业中，整体跌幅为0.53%。Inhibrx Biosciences, Inc.公司简介：Inhibrx Biosciences Inc是一家临床阶段的生物制药公司，利用其专有的模块化蛋白质工程平台开发了一系列新型生物治疗候选药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306232509a2629e6a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306232509a2629e6a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","INBX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516677324","title":"Inhibrx Biosciences, Inc.盘中异动 早盘股价大跌5.01%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516677324","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516677324?lang=zh_cn&edition=full","pubTime":"2025-03-04 22:37","pubTimestamp":1741099056,"startTime":"0","endTime":"0","summary":"北京时间2025年03月04日22时37分，Inhibrx Biosciences, Inc.股票出现波动，股价急速跳水5.01%。Inhibrx Biosciences, Inc.股票所在的生物技术行业中，整体跌幅为0.09%。Inhibrx Biosciences, Inc.公司简介：Inhibrx Biosciences Inc是一家临床阶段的生物制药公司，利用其专有的模块化蛋白质工程平台开发了一系列新型生物治疗候选药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025030422373696394681&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025030422373696394681&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","INBX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516030626","title":"Inhibrx Biosciences, Inc.盘中异动 急速上涨5.52%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516030626","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516030626?lang=zh_cn&edition=full","pubTime":"2025-03-01 04:21","pubTimestamp":1740774085,"startTime":"0","endTime":"0","summary":"北京时间2025年03月01日04时21分，Inhibrx Biosciences, Inc.股票出现波动，股价快速上涨5.52%。Inhibrx Biosciences, Inc.股票所在的生物技术行业中，整体涨幅为0.44%。Inhibrx Biosciences, Inc.公司简介：Inhibrx Biosciences Inc是一家临床阶段的生物制药公司，利用其专有的模块化蛋白质工程平台开发了一系列新型生物治疗候选药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250301042126abe138c3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250301042126abe138c3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","INBX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2513296523","title":"Inhibrx Biosciences, Inc.盘中异动 股价大涨12.34%","url":"https://stock-news.laohu8.com/highlight/detail?id=2513296523","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2513296523?lang=zh_cn&edition=full","pubTime":"2025-02-21 22:33","pubTimestamp":1740148429,"startTime":"0","endTime":"0","summary":"北京时间2025年02月21日22时33分，Inhibrx Biosciences, Inc.股票出现波动，股价急速拉升12.34%。Inhibrx Biosciences, Inc.股票所在的生物技术行业中，整体涨幅为0.34%。Inhibrx Biosciences, Inc.公司简介：Inhibrx Biosciences Inc是一家临床阶段的生物制药公司，利用其专有的模块化蛋白质工程平台开发了一系列新型生物治疗候选药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250221223350abd7b01d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250221223350abd7b01d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["INBX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2509259695","title":"Inhibrx Biosciences, Inc.盘中异动 临近收盘股价大涨5.19%","url":"https://stock-news.laohu8.com/highlight/detail?id=2509259695","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2509259695?lang=zh_cn&edition=full","pubTime":"2025-02-06 04:57","pubTimestamp":1738789060,"startTime":"0","endTime":"0","summary":"北京时间2025年02月06日04时57分，Inhibrx Biosciences, Inc.股票出现异动，股价急速上涨5.19%。Inhibrx Biosciences, Inc.股票所在的生物技术行业中，整体涨幅为1.97%。其相关个股中，Immatics N V C/Wts 01/07/2025 、Invivyd, Inc.、Transcode Therapeutics, Inc.涨幅较大，Pasithea Therapeutics Corp.、Transcode Therapeutics, Inc.、Oragenics Inc.较为活跃，换手率分别为4731.93%、2453.39%、1790.40%，振幅较大的相关个股有Oragenics Inc.、Invivyd, Inc.、Transcode Therapeutics, Inc.，振幅分别为132.24%、108.79%、99.51%。Inhibrx Biosciences, Inc.公司简介：Inhibrx Biosciences Inc是一家临床阶段的生物制药公司，利用其专有的模块化蛋白质工程平台开发了一系列新型生物治疗候选药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250206045740abc3cc61&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250206045740abc3cc61&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","INBX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2508141018","title":"Inhibrx Biosciences, Inc.盘中异动 急速下挫5.23%报12.87美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2508141018","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2508141018?lang=zh_cn&edition=full","pubTime":"2025-02-03 23:00","pubTimestamp":1738594837,"startTime":"0","endTime":"0","summary":"北京时间2025年02月03日23时00分，Inhibrx Biosciences, Inc.股票出现异动，股价大幅跳水5.23%。Inhibrx Biosciences, Inc.股票所在的生物技术行业中，整体跌幅为0.62%。Inhibrx Biosciences, Inc.公司简介：Inhibrx Biosciences Inc是一家临床阶段的生物制药公司，利用其专有的模块化蛋白质工程平台开发了一系列新型生物治疗候选药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250203230037961700f7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250203230037961700f7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["INBX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2507621306","title":"Inhibrx Biosciences, Inc.盘中异动 早盘急速上涨5.77%","url":"https://stock-news.laohu8.com/highlight/detail?id=2507621306","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2507621306?lang=zh_cn&edition=full","pubTime":"2025-01-30 22:37","pubTimestamp":1738247830,"startTime":"0","endTime":"0","summary":"北京时间2025年01月30日22时37分，Inhibrx Biosciences, Inc.股票出现波动，股价大幅拉升5.77%。Inhibrx Biosciences, Inc.股票所在的生物技术行业中，整体涨幅为0.05%。Inhibrx Biosciences, Inc.公司简介：Inhibrx Biosciences Inc是一家临床阶段的生物制药公司，利用其专有的模块化蛋白质工程平台开发了一系列新型生物治疗候选药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250130223710abbd4d61&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250130223710abbd4d61&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","INBX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2506054503","title":"Inhibrx Biosciences, Inc.盘中异动 早盘急速拉升7.41%报14.13美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2506054503","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2506054503?lang=zh_cn&edition=full","pubTime":"2025-01-27 23:02","pubTimestamp":1737990134,"startTime":"0","endTime":"0","summary":"北京时间2025年01月27日23时02分，Inhibrx Biosciences, Inc.股票出现异动，股价快速上涨7.41%。截至发稿，该股报14.13美元/股，成交量1.2927万股，换手率0.09%，振幅3.50%。Inhibrx Biosciences, Inc.股票所在的生物技术行业中，整体涨幅为0.88%。Inhibrx Biosciences, Inc.公司简介：Inhibrx Biosciences Inc是一家临床阶段的生物制药公司，利用其专有的模块化蛋白质工程平台开发了一系列新型生物治疗候选药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202501272302149874b4f4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202501272302149874b4f4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["INBX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2505040684","title":"Inhibrx Biosciences, Inc.盘中异动 大幅下挫5.22%","url":"https://stock-news.laohu8.com/highlight/detail?id=2505040684","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2505040684?lang=zh_cn&edition=full","pubTime":"2025-01-24 03:26","pubTimestamp":1737660363,"startTime":"0","endTime":"0","summary":"北京时间2025年01月24日03时26分，Inhibrx Biosciences, Inc.股票出现异动，股价快速下跌5.22%。Inhibrx Biosciences, Inc.股票所在的生物技术行业中，整体涨幅为1.15%。Inhibrx Biosciences, Inc.公司简介：Inhibrx Biosciences Inc是一家临床阶段的生物制药公司，利用其专有的模块化蛋白质工程平台开发了一系列新型生物治疗候选药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202501240326039870ee67&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202501240326039870ee67&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["INBX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2505903277","title":"Inhibrx Biosciences, Inc.盘中异动 股价大涨5.40%报14.22美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2505903277","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2505903277?lang=zh_cn&edition=full","pubTime":"2025-01-21 23:14","pubTimestamp":1737472469,"startTime":"0","endTime":"0","summary":"北京时间2025年01月21日23时14分，Inhibrx Biosciences, Inc.股票出现波动，股价快速拉升5.40%。截至发稿，该股报14.22美元/股，成交量1.2809万股，换手率0.09%，振幅3.97%。Inhibrx Biosciences, Inc.股票所在的生物技术行业中，整体涨幅为1.22%。Inhibrx Biosciences, Inc.公司简介：Inhibrx Biosciences Inc是一家临床阶段的生物制药公司，利用其专有的模块化蛋白质工程平台开发了一系列新型生物治疗候选药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250121231429960bc237&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250121231429960bc237&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","INBX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2503990758","title":"Inhibrx Biosciences, Inc.盘中异动 股价大涨6.90%","url":"https://stock-news.laohu8.com/highlight/detail?id=2503990758","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2503990758?lang=zh_cn&edition=full","pubTime":"2025-01-16 22:33","pubTimestamp":1737038019,"startTime":"0","endTime":"0","summary":"北京时间2025年01月16日22时33分，Inhibrx Biosciences, Inc.股票出现异动，股价大幅拉升6.90%。Inhibrx Biosciences, Inc.股票所在的生物技术行业中，整体跌幅为0.01%。Inhibrx Biosciences, Inc.公司简介：Inhibrx Biosciences Inc是一家临床阶段的生物制药公司，利用其专有的模块化蛋白质工程平台开发了一系列新型生物治疗候选药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202501162233409606085e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202501162233409606085e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["INBX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.inhibrx.com","stockEarnings":[{"period":"1week","weight":0.045},{"period":"1month","weight":-0.1429},{"period":"3month","weight":0.3555},{"period":"6month","weight":0.0913},{"period":"1year","weight":5.3687},{"period":"ytd","weight":0.1786}],"compareEarnings":[{"period":"1week","weight":0.018},{"period":"1month","weight":0.0151},{"period":"3month","weight":0.1344},{"period":"6month","weight":0.1092},{"period":"1year","weight":0.245},{"period":"ytd","weight":0.1003}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Inhibrx Biosciences, Inc.于2024年1月8日根据特拉华州法律成立，是Inhibrx, Inc.的直接全资子公司。该公司是一家临床阶段的生物制药公司，拥有一系列新型候选生物治疗药物，使用其专有的模块化蛋白质工程平台开发。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.100441},{"month":2,"riseRate":0,"avgChangeRate":-0.118883},{"month":3,"riseRate":0.25,"avgChangeRate":-0.108872},{"month":4,"riseRate":0.5,"avgChangeRate":-0.034815},{"month":5,"riseRate":0.25,"avgChangeRate":-0.039218},{"month":6,"riseRate":0.666667,"avgChangeRate":0.088726},{"month":7,"riseRate":0.666667,"avgChangeRate":0.111417},{"month":8,"riseRate":1,"avgChangeRate":0.030836},{"month":9,"riseRate":0.75,"avgChangeRate":0.016607},{"month":10,"riseRate":0.5,"avgChangeRate":0.197255},{"month":11,"riseRate":0.75,"avgChangeRate":0.223807},{"month":12,"riseRate":0.75,"avgChangeRate":0.232405}],"exchange":"NASDAQ","name":"Inhibrx Biosciences","nameEN":"Inhibrx Biosciences"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Inhibrx Biosciences(INBX)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Inhibrx Biosciences(INBX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Inhibrx Biosciences,INBX,Inhibrx Biosciences股票,Inhibrx Biosciences股票老虎,Inhibrx Biosciences股票老虎国际,Inhibrx Biosciences行情,Inhibrx Biosciences股票行情,Inhibrx Biosciences股价,Inhibrx Biosciences股市,Inhibrx Biosciences股票价格,Inhibrx Biosciences股票交易,Inhibrx Biosciences股票购买,Inhibrx Biosciences股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Inhibrx Biosciences(INBX)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Inhibrx Biosciences(INBX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}